Biomea Fusion Q4 net loss $29.3M; cash drops to $58.6M; interim CEO appointed, pivots to diabetes

Biomea Fusion, Inc.

2025-Q1 EPS reported -$0.80

Net loss $29.3M for Q4 2024 ($34.9M in Q4 2023); FY net loss $138.4M vs $117.3M.
Cash reserves $58.6M at Dec 31, 2024, down from $177.2M a year earlier.
Mick Hitchcock appointed interim CEO; all oncology trials terminated, focus shifts to diabetes/obesity.
Icovamenib in severe insulin-deficient T2D: 1.47% HbA1c reduction at Week 26; FDA meeting planned H1 2025.
BMF-650 (oral GLP-1 RA) IND submission planned H2 2025; preclinical appetite suppression data reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.